NCT04148209View on ClinicalTrials.gov

Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions
Healthy
Interventions
DRUG

PF-07081532

Participants will receive single ascending doses PF-07081532

DRUG

Placebo

Participants will receive placebo

Trial Locations (1)

B-1070

Brussels Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04148209 - Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter